Download biomedica product list
Pediatric Liver Transplantation
Thirty-Year Outcomes of Immunosuppression Modulation
Over the past six decades, organ transplantation, especially pediatric liver transplantation, has revolutionized medical care by offering life-saving treatment options for children with end-stage liver disease (1). In a recent study, researchers investigated on how immunosuppressive therapy affects liver transplant outcomes in children during a thirty-year follow-up (2). Although pediatric liver transplantation is a life-saving procedure, it presents ongoing long-term challenges associated with immunosuppression (IS). Patients were classified according to their immunosuppression status at the final follow-up into three groups.
Pediatric Liver Transplantation
Thirty-Year Outcomes of Immunosuppression Modulation
Key Findings:
• The favorable histology and antibody profile observed in the IS-free group suggest the potential for sustained immune tolerance.
• Ongoing fibrosis in the IS-resumption group underscores the limitations of traditional immunosuppression strategies.
• Regular histological assessments and antibody monitoring may be beneficial for long-term immunosuppression management in pediatric liver transplant patients.
C4d a biomarker of transplant rejection
BIOMEDICA´s Anti-C4d Antibody Features – for the identification of human complement split product C4d in paraffin and frozen sections as well as by flow cytometry.
Anti-C4d Antibody | BI-RC4D
- TRUSTED – widely cited in over 100 citations
- MULTI-USE – for immunohistochemistry on paraffin embedded tissue and frozen sections
- The C4d antibody has been utilized in kidney, heart, liver and other transplants
- working protocol
Anti-C4d Antibody (FITC) | BI-RC4D-FITC
- Protocol for cell- or solid-phase bound C4 and C4d split product by flow cytometry
- working protocol
-Explore our anti-C4d antibodies for ICH and FITC.